Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

138.34
+0.85500.62%
Volume:351.50K
Turnover:48.68M
Market Cap:263.94B
PE:20.91
High:138.91
Open:138.77
Low:138.08
Close:137.48
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:1.24
T/O Rate:0.02%
Dividend:4.67
Dividend Rate:3.37%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.35
PE(LYR):19.35

Loading ...

Dow Jones Top Company Headlines at 9 PM ET: Amazon Cargo Plane Overshoots Runway in Miami, Killing Five People | Carmakers ...

Dow Jones
·
Sep 07

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

Dow Jones
·
Sep 06

Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal

Dow Jones
·
Sep 05

Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex

Dow Jones
·
Sep 05

Novartis Pelacarsen Fails Phase III Cardiovascular Outcomes Trial

MT Newswires Live
·
Sep 05

Novartis announces Phase 3 pelacarsen study did not meet primary endpoint

TIPRANKS
·
Sep 05

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Dow Jones
·
Sep 05

Movement Alert|Novartis AG Falls 6.24% in After-Hours Trading, Trading at $154.33

Market Focus
·
Sep 05

Novartis AG Falls Friday, Underperforms Market

Dow Jones
·
Sep 05

Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects

Dow Jones
·
Sep 04

Dow Jones Top Company Headlines at 11 PM ET: the 'Deeply Nerdy' Founders Behind Nvidia's $13 Billion Bet on Hugging Face | Musk's ...

Dow Jones
·
Sep 04

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

TIPRANKS
·
Sep 03

Novartis AG Rises Wednesday, Outperforms Market

Dow Jones
·
Sep 03

Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion

MT Newswires Live
·
Sep 02

Alteogen enters option, license agreement with Novartis

TIPRANKS
·
Sep 02

Novartis Trial Suspensions to Have Limited Financial Impact

Dow Jones
·
Sep 02

H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi

TIPRANKS
·
Sep 01

Novartis MS Trials Open Door to Multibillion-Dollar Sales Opportunity

Dow Jones
·
Sep 01

Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials

TIPRANKS
·
Sep 01

Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement

TradingKey
·
Sep 01